ASweetLife Team, Author at ASweetLife

FDA Approves Byetta for Use with Lantus Insulin in the U.S.

The U.S. Food and Drug Administration (FDA) has approved a new use for Amylin and Eli Lilly's type 2 diabetes drug, Byetta (exenatide) injection. Byetta is now approved as an add-on therapy to insulin glargine (Lantus), with or without metformin and/or a thiazolidinedione (TZD), for adults with type 2 diabetes...

ALR Tech Receives FDA Clearance for Remote Monitoring System for Diabetes

ALR Technologies Inc received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Health-e-Connect (HeC) System for remote monitoring of patients in support of effective diabetes management programs. The 510(k) clearance enables the company to commence with the United States marketing and sales launch of its HeC platform...

Watch TEDxDelMar Live!

For those of us who can't attend the amazing TEDxDelMar conference on type 1 diabetes, we still have the opportunity to see it live. You can access the Tedx channel from TEDxDelMar's website http://www.tedxdelmar.com or from TED.com http://www.livestream.com/tedx

Victoza, Novo Nordisk’s Type 2 Diabetes Drug, Available in China

Victoza, Novo Nordisks best selling type 2 diabetes drug is now commercially available in China. Victoza, (liraglutide injection), the first once-daily human Glucagon-Like Peptide-1 (GLP-1) analog, was approved for type 2 diabetes by the Chinese State Food and Drug Administration in March 2011...

FDA Approves New Combination Drug, Juvisync, for Treatment of Type 2 Diabetes

The FDA has approved a new treatment for type 2 diabetes that combines the glucose-lowering medication sitagliptin, the active component of JANUVIA, with the cholesterol-lowering medication ZOCOR (simvastatin). The new drug, produced by Merck, known as MSD outside the United States and Canada, will be...

TEDxDelMar Tickets on Sale Now!

On October 15, 2011, the top names in diabetes research will be at TEDxDelMar in San Diego, discussing the future of diabetes care and cure. Don’t miss out on a chance to hear Jeff Bluestone, Bill Polonsky, Steven Edelman, and many more…

Novo Nordisk Requests FDA Approval for Ultra-Long-Acting Insulin Degludec

Novo Nordisk filed two new drug applications for the approval of ultra-long-acting insulin degludec and the co-formulation, insulin degludec/insulin aspart (DegludecPlus) by the U.S. Food and Drug Administration. These new insulin analogs have been developed for the treatment of people with type 1 and type 2 diabetes.

New Roche Accu-Chek Aviva Plus Glucose Test Strips Receive FDA Clearance

Roche announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Accu-Chek Aviva Plus test system. The new maltose-independent test strip is designed to prevent the interference of maltose on blood sugar readings which can occur in rare cases...

Diabetes Essentials, part 2

Something I hate about myself has become essential to my diabetes care...

Biodel’s Ultra Rapid Insulin Fails in Second Phase 1 Trial

Biodel's ultra-rapid-acting formulations of recombinant human insulin, BIOD-105 and BIOD-107, failed to meet the company's target product profile in the second phase 1 clinical trial at Oregon Health and Sciences University and will therefore not be advancing to phase 2 trials. The top-line results from the phase...